WO2003054194A3 - Modifizierte tridegine, ihre herstellung und verwendung als transglutaminase-inhibitoren - Google Patents

Modifizierte tridegine, ihre herstellung und verwendung als transglutaminase-inhibitoren Download PDF

Info

Publication number
WO2003054194A3
WO2003054194A3 PCT/EP2002/014684 EP0214684W WO03054194A3 WO 2003054194 A3 WO2003054194 A3 WO 2003054194A3 EP 0214684 W EP0214684 W EP 0214684W WO 03054194 A3 WO03054194 A3 WO 03054194A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
production
seq
amino acid
polypeptides
Prior art date
Application number
PCT/EP2002/014684
Other languages
English (en)
French (fr)
Other versions
WO2003054194A2 (de
Inventor
Helmut Giersiefen
Johannes Stoeckel
Tanja Pamp
Marion Ohlmann
Original Assignee
Curacyte Ag
Helmut Giersiefen
Johannes Stoeckel
Tanja Pamp
Marion Ohlmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001163333 external-priority patent/DE10163333B4/de
Application filed by Curacyte Ag, Helmut Giersiefen, Johannes Stoeckel, Tanja Pamp, Marion Ohlmann filed Critical Curacyte Ag
Priority to EP02805347A priority Critical patent/EP1458866B1/de
Priority to DE50211988T priority patent/DE50211988D1/de
Priority to AU2002366874A priority patent/AU2002366874A1/en
Priority to JP2003554897A priority patent/JP2005513141A/ja
Priority to US10/498,752 priority patent/US20060246046A1/en
Priority to CA002471373A priority patent/CA2471373A1/en
Publication of WO2003054194A2 publication Critical patent/WO2003054194A2/de
Publication of WO2003054194A3 publication Critical patent/WO2003054194A3/de
Priority to US12/406,745 priority patent/US20090226415A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft modifizierte Tridegine, Polypeptide abgeleitet von SEQ ID No. 1, wobei die Modifikation darin besteht, dass mindestens ein Cysteinrest und/oder eine der folgenden Aminosäuren - Lys2, Lys7, His10, Gly12, Leu24, Tyr31, Phe34, Arg39, Ile45, Met48, Asp50, Pro55, Phe58, Asn60, Pro65, Arg66 - durch eine andere Aminosäure substituiert ist, und/oder N- und C-terminus deletiert sind, wobei das verbleibende Polypeptid mindestens die Aminosäuresequenz DDIYQRXVXFPXLPL (SEQ ID NO.) enthält, und/oder eine Kovalente Verknüpfung mit Polyethylenglykol besteht. Die erfindungsgemässen Polypeptide sind neue Inhibitoren von Transglutaminasen, insbesondere des Faktors XIIIa, des terminalen Enzyms der Blutgerinnungs-Kaskade. Die vorliegende Erfindung betrifft ebenso Verfahren zur Herstellung dieser Inhibitoren, sowie deren Verwendung als Transglutaminase-Inhibitoren.
PCT/EP2002/014684 2001-12-21 2002-12-20 Modifizierte tridegine, ihre herstellung und verwendung als transglutaminase-inhibitoren WO2003054194A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP02805347A EP1458866B1 (de) 2001-12-21 2002-12-20 Modifizierte tridegine, ihre herstellung und verwendung als transglutaminase-inhibitoren
DE50211988T DE50211988D1 (de) 2001-12-21 2002-12-20 Modifizierte tridegine, ihre herstellung und verwendung als transglutaminase-inhibitoren
AU2002366874A AU2002366874A1 (en) 2001-12-21 2002-12-20 Modified tridegins, production and use thereof as transglutaminase inhibitors
JP2003554897A JP2005513141A (ja) 2001-12-21 2002-12-20 修飾トリデジン（ｔｒｉｄｅｇｉｎｓ）、その製剤、およびトランスグルタミナーゼ阻害剤としてのその使用
US10/498,752 US20060246046A1 (en) 2001-12-21 2002-12-20 Modified tridegins, production and use thereof as transglutaminase inihibitors
CA002471373A CA2471373A1 (en) 2001-12-21 2002-12-20 Modified tridegins, their preparation and their use as transglutaminase inhibitors
US12/406,745 US20090226415A1 (en) 2001-12-21 2009-03-18 Modified tridegins, production and use thereof as transglutaminase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10163333.5 2001-12-21
DE2001163333 DE10163333B4 (de) 2001-12-21 2001-12-21 Modifizierte Tridegine, ihre Herstellung deren Verwendung als Transglutaminase Inhibitoren und diese enthaltende Arzneimittel und Kombinationspräparate
DE10258159.2 2002-12-12
DE10258159 2002-12-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/406,745 Continuation US20090226415A1 (en) 2001-12-21 2009-03-18 Modified tridegins, production and use thereof as transglutaminase inhibitors

Publications (2)

Publication Number Publication Date
WO2003054194A2 WO2003054194A2 (de) 2003-07-03
WO2003054194A3 true WO2003054194A3 (de) 2004-01-08

Family

ID=26010841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/014684 WO2003054194A2 (de) 2001-12-21 2002-12-20 Modifizierte tridegine, ihre herstellung und verwendung als transglutaminase-inhibitoren

Country Status (8)

Country Link
US (2) US20060246046A1 (de)
EP (1) EP1458866B1 (de)
JP (1) JP2005513141A (de)
AT (1) ATE390481T1 (de)
AU (1) AU2002366874A1 (de)
CA (1) CA2471373A1 (de)
DE (1) DE50211988D1 (de)
WO (1) WO2003054194A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121165A1 (ja) * 2005-05-12 2006-11-16 Ajinomoto Co., Inc. タンパク質の製造法
GB0515003D0 (en) * 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
CN109749948A (zh) * 2019-03-05 2019-05-14 天津科技大学 一种利用tef1启动子调控黏玉米谷氨酰胺转氨酶表达的重组毕赤酵母菌株及构建方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034890A2 (en) * 1995-05-05 1996-11-07 Biopharm Research & Development Limited Inhibitors of fibrin cross-linking and/or transglutaminases
WO2000049039A2 (de) * 1999-02-19 2000-08-24 Merck Patent Gmbh Glucose-dehydrogenase-fusionsproteine und ihre verwendung in expressionssystemen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269827A (en) * 1980-06-23 1981-05-26 The Massachusetts General Hospital Process and composition for reducing blood pressure
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US6265187B1 (en) * 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US5470957A (en) * 1993-10-01 1995-11-28 President And Fellows Of Harvard College Immunoinhibitors of factor XIII

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034890A2 (en) * 1995-05-05 1996-11-07 Biopharm Research & Development Limited Inhibitors of fibrin cross-linking and/or transglutaminases
WO2000049039A2 (de) * 1999-02-19 2000-08-24 Merck Patent Gmbh Glucose-dehydrogenase-fusionsproteine und ihre verwendung in expressionssystemen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WALLIS, R.B. ET AL.: "Reduction of plasma clot stability by a novel factor XIIIa inhibitor from the Giant Amazon Leech, Haementeria ghilianii", BLOOD COAGULATION & FIBRINOLYSIS, vol. 8, no. 5, July 1997 (1997-07-01), pages 291 - 295, XP008015989 *

Also Published As

Publication number Publication date
CA2471373A1 (en) 2003-07-03
DE50211988D1 (de) 2008-05-08
WO2003054194A2 (de) 2003-07-03
US20060246046A1 (en) 2006-11-02
AU2002366874A1 (en) 2003-07-09
ATE390481T1 (de) 2008-04-15
JP2005513141A (ja) 2005-05-12
EP1458866B1 (de) 2008-03-26
US20090226415A1 (en) 2009-09-10
EP1458866A2 (de) 2004-09-22

Similar Documents

Publication Publication Date Title
Dziuba et al. Computer-aided characteristics of proteins as potential precursors of bioactive peptides SO POLIMERY
EP2110385A8 (de) Stabilisierte Faktor VIII mit manipulierten Disulfid-Bindungen
WO2005017149A8 (en) Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
EP1308459A3 (de) Vollständige cDNA-Sequenzen
WO2005115306A3 (de) Keratin-bindende polypeptide
EP1440981A3 (de) Vollständige humane cDNS
EP1801206A4 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
MXPA03002218A (es) Peptidos antimicrobianos y metodos de uso.
WO2006056885A3 (en) Igf-1 isoforms
GEP20115196B (en) Neublastin variants
KR960704934A (ko) 항혈전활성을 갖는 펩티드 및 이의 제조방법(Peptide having antithrombotic activity and process for producing the same)
WO2007030519A3 (en) Stabilized glp-1 analogs
WO2002061076A1 (en) Adiponectin-associated protein
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2006097432A3 (de) Keratin-biktdende desmoplakinpolypeptidsequenzen
WO2007058267A8 (ja) 新規タンパク質及びそれをコードする遺伝子
WO2002092758A8 (en) Gastrokines and derived peptides including inhibitors
WO2003054194A3 (de) Modifizierte tridegine, ihre herstellung und verwendung als transglutaminase-inhibitoren
WO2006090282A3 (en) Recombinant inhibitor proteins of an hk14 protease and use thereof
IL162133A0 (en) Method of increasing protein expression, proteins and polynucleotides
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
DK0828004T3 (da) Proteindisulfidisomerase-gen afledt af stamme af methylotrof gær
DE60036676D1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
DE60313718D1 (de) Zusammensetzung zur Zellkultur, die Polyethylenglykol enthält
WO2023144753A3 (en) Recombinant expression of fumonisin esterase, compositions and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002805347

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003554897

Country of ref document: JP

Ref document number: 2002366874

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2471373

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002805347

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2006246046

Country of ref document: US

Ref document number: 10498752

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10498752

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002805347

Country of ref document: EP